Previous studies have explored the use of PD-L1, tumor mutational burden (TMB) and tumor-associated immune cells (TAICs) to predict the clinical outcome of immunotherapy (3, 9–13), and based on those studies, PD-L1 and TMB have been included in the NCCN guidelines. This evidence concerns the gene CD274 and neoplasm.